Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.52 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.52 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13683459 | 0.87 | CARM1 (0.39) | CARM1PRMT6PRMT1PRMT8POLB | |
| SCHEMBL12245557 | 0.87 | SIGMAR1 (0.50) | CARM1PRMT6PRMT1PRMT8POLB | |
| SCHEMBL10130266 | 0.87 | CARM1 (0.39) | CARM1PRMT6PRMT1PRMT8POLB | |
| SCHEMBL17307156 | 0.87 | CARM1 (0.39) | CARM1PRMT6PRMT1PRMT8POLB | |
| SCHEMBL13602668 | 0.85 | SIGMAR1 (0.49) | CARM1PRMT6PRMT1PRMT8SIGMAR1 | |
| SCHEMBL19200880 | 0.83 | CARM1 (0.48) | CARM1PRMT6PRMT1PRMT8POLB | |
| SCHEMBL16247250 | 0.82 | CACNA1I (0.40) | KCNH2CACNA1I | |
| SCHEMBL19200875 | 0.81 | CARM1 (0.47) | CARM1PRMT6PRMT1PRMT8POLB | |
| SCHEMBL23919061 | 0.80 | CACNA1I (0.44) | KCNH2CACNA1I | |
| SCHEMBL10032110 | 0.80 | KCNA3 (0.45) | KCNA3KCNH2CACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11207298-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-28 | — | — | US | disclosed |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. | 2021-04-01 | — | — | US | disclosed |
| US-10766865-B2 | PKM2 modulators and methods for their use | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200237766-A1 | PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER | SUMITOMO PHARMA ONCOLOGY, INC. | 2020-07-30 | — | — | US | disclosed |
| US-10472328-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20190119219-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10207996-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-09-30 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | CARM1 736/4885PRMT6 218/4885PRMT1 225/4885 |
| US-11207298-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | CARM1 2045/4885PRMT6 2710/4885PRMT1 2028/4885 |
| US-10766865-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | CARM1 224/4885PRMT6 162/4885PRMT1 122/4885 |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | CARM1 3036/4885PRMT6 3926/4885PRMT1 2381/4885 |
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | TP53, BCOR, HPGDS | CARM1 932/4885PRMT6 2792/4885PRMT1 3423/4885 |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | CARM1 3887/4885PRMT6 1456/4885PRMT1 1280/4885 |
| US-10472328-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | CARM1 224/4885PRMT6 162/4885PRMT1 122/4885 |
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | CARM1 1348/4885PRMT6 1525/4885PRMT1 397/4885 |
| US-10207996-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | CARM1 224/4885PRMT6 162/4885PRMT1 122/4885 |
| US-20200237766-A1 | PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER | PDK1, PDK2, PCK2 | CARM1 611/4885PRMT6 487/4885PRMT1 647/4885 |
| US-20190119219-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | CARM1 224/4885PRMT6 162/4885PRMT1 122/4885 |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | CARM1 2204/4885PRMT6 2790/4885PRMT1 2864/4885 |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | KRAS, NRAS, APC | CARM1 2379/4885PRMT6 1205/4885PRMT1 976/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | CARM1 2204/4885PRMT6 2790/4885PRMT1 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.